Alliancebernstein L.P. Purchases New Shares in NewAmsterdam Pharma (NASDAQ:NAMS)

Alliancebernstein L.P. purchased a new position in NewAmsterdam Pharma (NASDAQ:NAMS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,858,065 shares of the company’s stock, valued at approximately $47,752,000.

A number of other institutional investors have also added to or reduced their stakes in the company. FMR LLC grew its position in shares of NewAmsterdam Pharma by 35.6% in the 3rd quarter. FMR LLC now owns 330,412 shares of the company’s stock worth $5,485,000 after buying an additional 86,712 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in NewAmsterdam Pharma by 1,231.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock worth $3,972,000 after purchasing an additional 221,305 shares during the period. Walleye Capital LLC bought a new position in shares of NewAmsterdam Pharma during the third quarter valued at approximately $779,000. Janus Henderson Group PLC lifted its holdings in shares of NewAmsterdam Pharma by 51.1% during the third quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock valued at $25,607,000 after purchasing an additional 520,772 shares during the last quarter. Finally, Quarry LP lifted its holdings in shares of NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS opened at $15.81 on Friday. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -6.08 and a beta of -0.04. The stock has a 50-day moving average of $21.13 and a 200 day moving average of $21.27. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to analysts’ expectations of $3.30 million. On average, equities analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NAMS has been the subject of a number of analyst reports. Needham & Company LLC reduced their price objective on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Scotiabank raised their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Thursday, February 27th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Royal Bank of Canada restated an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, NewAmsterdam Pharma has a consensus rating of “Buy” and an average target price of $43.33.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. This represents a 90.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director James N. Topper acquired 1,135 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was acquired at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the acquisition, the director now owns 3,013,569 shares of the company’s stock, valued at $67,775,166.81. The trade was a 0.04 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.